Adaptive Biotechnologies Corp (NASDAQ: ADPT) Stock In Prove Me State

Adaptive Biotechnologies Corp (ADPT) concluded trading on Wednesday at a closing price of $2.68, with 4.23 million shares of worth about $11.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -48.36% during that period and on April 3, 2024 the price saw a loss of about -10.07%. Currently the company’s common shares owned by public are about 145.08M shares, out of which, 138.51M shares are available for trading.

Stock saw a price change of -6.94% in past 5 days and over the past one month there was a price change of -32.83%. Year-to-date (YTD), ADPT shares are showing a performance of -45.31% which decreased to -69.65% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.61 but also hit the highest price of $9.08 during that period. The average intraday trading volume for Adaptive Biotechnologies Corp shares is 1.45 million. The stock is currently trading -19.23% below its 20-day simple moving average (SMA20), while that difference is down -27.19% for SMA50 and it goes to -47.83% lower than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Adaptive Biotechnologies Corp (NASDAQ: ADPT) currently have 145.08M outstanding shares and institutions hold larger chunk of about 95.41% of that.

The stock has a current market capitalization of $388.84M and its 3Y-monthly beta is at 1.24. It has posted earnings per share of -$1.56 in the same period. It has Quick Ratio of 4.50 while making debt-to-equity ratio of 0.74. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ADPT, volatility over the week remained 9.15% while standing at 8.04% over the month.

Analysts are in expectations that Adaptive Biotechnologies Corp (ADPT) stock would likely to be making an EPS of -$0.35 in the current quarter, while forecast for next quarter EPS is -$0.33 and it is -$1.06 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.37 which is -$0.33 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.4 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 15.99% while it is estimated to increase by 17.65% in next year. EPS is likely to grow at an annualized rate of 21.60% for next 5-years, compared to annual growth of -32.91% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on July 05, 2023 offering an Overweight rating for the stock and assigned a target price of $15 to it. Coverage by Scotiabank stated Adaptive Biotechnologies Corp (ADPT) stock as a Sector outperform in their note to investors on January 05, 2023, suggesting a price target of $15 for the stock. On December 21, 2022, Piper Sandler Upgrade their recommendations, while on August 25, 2022, Credit Suisse Initiated their ratings for the stock with a price target of $8. Stock get a Neutral rating from Piper Sandler on June 03, 2022.

Most Popular

Related Posts